BTIG Reaffirms Buy Rating for Ovid Therapeutics

Analysts maintain $4 price target on the biotech company's stock

Mar. 27, 2026 at 12:06pm

Got story updates? Submit your updates here. ›

BTIG Research has reissued a "buy" rating and $4.00 price target on shares of Ovid Therapeutics (NASDAQ:OVID). The analysts cited the company's progress in developing therapies for rare neurological disorders such as Angelman syndrome and Fragile X syndrome.

Why it matters

Ovid Therapeutics is a clinical-stage biotech focused on developing treatments for rare neurological conditions, an area with high unmet medical need. The BTIG analysts' continued confidence in the company's lead drug candidate OV101 and its overall pipeline suggests they believe Ovid has promising prospects despite the challenges of developing drugs for small patient populations.

The details

In their research report, the BTIG analysts reiterated their "buy" rating and $4.00 price target on Ovid Therapeutics. This price target represents a potential upside of 62.60% from the company's previous closing price. The analysts cited Ovid's progress in advancing OV101, a selective extrasynaptic GABAA receptor agonist, through clinical trials for the treatment of Angelman syndrome and Fragile X syndrome.

  • BTIG Research issued the research report on Thursday, March 27, 2026.

The players

Ovid Therapeutics

A clinical-stage biopharmaceutical company focused on developing therapies for rare neurological disorders.

BTIG Research

An independent equity research and trading firm that provides research coverage on Ovid Therapeutics.

Got photos? Submit your photos here. ›

The takeaway

Ovid Therapeutics' continued progress in advancing its pipeline of rare disease treatments, particularly its lead candidate OV101, has maintained the confidence of analysts at BTIG Research. This suggests the company remains well-positioned to potentially address significant unmet medical needs in the neurological disorder space.